Brief: Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis
07/09/2017 13:30
Sept 7 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O
* Anthera Pharmaceuticals surpasses 50% milestone for
screening of patients in result phase 3 clinical study of
Sollpura in cystic fibrosis
* Anthera Pharmaceuticals Inc - Topline data are expected
at end of 2017 to early 2018
Source text for Eikon: ID:nGNXOECDCa
Further company coverage: ANTH.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman